Enanta Pharmaceuticals, Inc. Share Price
Equities
ENTA
US29251M1062
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
12.47 USD | +3.92% | +3.66% | +32.52% |
Sales 2024 * | 69.71M 5.81B | Sales 2025 * | 72.54M 6.05B | Capitalization | 264M 22.03B |
---|---|---|---|---|---|
Net income 2024 * | -125M -10.43B | Net income 2025 * | -117M -9.76B | EV / Sales 2024 * | 3.79 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 3.64 x |
P/E ratio 2024 * |
-2.15
x | P/E ratio 2025 * |
-2.5
x | Employees | 145 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 93.91% |
Latest transcript on Enanta Pharmaceuticals, Inc.
1 day | +3.92% | ||
1 week | +3.66% | ||
1 month | -10.35% | ||
3 months | -18.76% | ||
6 months | +27.77% | ||
Current year | +32.52% |
Managers | Title | Age | Since |
---|---|---|---|
Jay Luly
CEO | Chief Executive Officer | 67 | 01/03/01 |
Paul Mellett
DFI | Director of Finance/CFO | 68 | 01/03/01 |
Chief Tech/Sci/R&D Officer | 50 | 08/22/08 |
Members of the board | Title | Age | Since |
---|---|---|---|
Mark Foletta
BRD | Director/Board Member | 63 | 29/20/29 |
Lesley Russell
BRD | Director/Board Member | 63 | 18/16/18 |
Bruce Carter
CHM | Chairman | 80 | 25/13/25 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.10% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
31/24/31 | 12.47 | +3.92% | 97,834 |
30/24/30 | 12 | +0.84% | 66,065 |
29/24/29 | 11.9 | -0.25% | 82,798 |
28/24/28 | 11.93 | -0.83% | 205,987 |
Delayed Quote Nasdaq, May 01, 2024 at 01:30 am IST
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+32.52% | 264M | |
+43.36% | 54.63B | |
-5.31% | 39.92B | |
+14.75% | 26.86B | |
-12.56% | 26.22B | |
-22.45% | 18.78B | |
+25.12% | 12.21B | |
+0.04% | 12.16B | |
+26.04% | 11.94B | |
-11.83% | 10.74B |
- Stock Market
- Equities
- ENTA Stock